Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
42
CL Quote, Financials, Valuation and Earnings
Last price:
$87.38
Seasonality move
:
2.49%
Day range:
$87.36 - $89.86
52-week range:
$79.69 - $109.30
Dividend yield:
2.26%
P/E ratio:
25.08x
P/S ratio:
3.59x
P/B ratio:
164.42x
Volume:
6M
Avg. volume:
4.2M
1-year change:
9.45%
Market cap:
$71.5B
Revenue:
$19.5B
EPS (TTM):
$3.49
Analysts' Opinion
-
Consensus RatingColgate-Palmolive has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 8 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $104.73, Colgate-Palmolive has an estimated upside of 19.64% from its current price of $87.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $83.11 representing 100% downside risk from its current price of $87.54.
Fair Value
-
According to the consensus of 16 analysts, Colgate-Palmolive has 19.64% upside to fair value with a price target of $104.73 per share.
CL vs. S&P 500
-
Over the past 5 trading days, Colgate-Palmolive has underperformed the S&P 500 by -6.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Colgate-Palmolive does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Colgate-Palmolive has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Colgate-Palmolive reported revenues of $5B.
Earnings Growth
-
Colgate-Palmolive has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Colgate-Palmolive reported earnings per share of $0.90.
Enterprise value:
79.1B
EV / Invested capital:
--
Price / LTM sales:
3.59x
EV / EBIT:
19.93x
EV / Revenue:
3.94x
PEG ratio (5yr expected):
0.31x
EV / Free cash flow:
23.27x
Price / Operating cash flow:
21.22x
Enterprise value / EBITDA:
17.28x
Gross Profit (TTM):
$12.1B
Return On Assets:
17.44%
Net Income Margin (TTM):
14.27%
Return On Equity:
434.96%
Return On Invested Capital:
30.94%
Operating Margin:
21.16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $17.7B | $19.1B | $20.1B | $4.9B | $5B | |
| Gross Profit | $10.2B | $11B | $12.1B | $2.9B | $3.1B | |
| Operating Income | $3.6B | $3.8B | $4.4B | $1B | $1.1B | |
| EBITDA | $3.5B | $3.6B | $4.6B | $1.2B | $1.2B | |
| Diluted EPS | $2.30 | $1.92 | $3.49 | $0.86 | $0.90 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.4B | $4.7B | $5.3B | $5.4B | $5.8B | |
| Total Assets | $15.5B | $15.9B | $16.3B | $16B | $16.8B | |
| Current Liabilities | $4.5B | $4.3B | $4.5B | $4.6B | $5.6B | |
| Total Liabilities | $14.4B | $14.9B | $15.2B | $15.6B | $15.9B | |
| Total Equity | $1.1B | $1B | $1.1B | $406M | $836M | |
| Total Debt | $7.2B | $7.7B | $8.2B | $8.7B | $8.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3B | $3.3B | $4B | $1.2B | $1.2B | |
| Cash From Investing | -$1.6B | -$772M | -$597M | -$161M | -$150M | |
| Cash From Financing | -$1.4B | -$2.5B | -$3.1B | -$846M | -$904M | |
| Free Cash Flow | $2.3B | $2.6B | $3.4B | $991M | $1B | |
CL
Sector
Market Cap
$71.5B
$327.2M
Price % of 52-Week High
80.09%
72.58%
Dividend Yield
2.26%
0%
Shareholder Yield
3.82%
2.68%
1-Year Price Total Return
9.45%
-13.49%
Beta (5-Year)
0.437
0.503
Dividend yield:
2.26%
Annualized payout:
$1.91
Payout ratio:
62.08%
Growth streak:
34 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$90.81
200-day SMA
Sell
Level
$96.17
Bollinger Bands (100)
Sell
Level
92.82 - 103.8
Chaikin Money Flow
Buy
Level
668.4M
20-day SMA
Sell
Level
$92.17
Relative Strength Index (RSI14)
Sell
Level
24.16
ADX Line
Sell
Level
42.56
Williams %R
Buy
Level
-97.3951
50-day SMA
Sell
Level
$93.40
MACD (12, 26)
Sell
Level
-1.32
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
283.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.6717)
Sell
CA Score
(Annual)
Level (-1.1079)
Buy
Beneish M-Score
(Annual)
Level (-2.8025)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (1.2934)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
Stock Forecast FAQ
In the current month, CL has received 7 Buy ratings 8 Hold ratings, and 1 Sell ratings. The CL average analyst price target in the past 3 months is $104.73.
-
Where Will Colgate-Palmolive Stock Be In 1 Year?
According to analysts, the consensus estimate is that Colgate-Palmolive share price will rise to $104.73 per share over the next 12 months.
-
What Do Analysts Say About Colgate-Palmolive?
Analysts are divided on their view about Colgate-Palmolive share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Colgate-Palmolive is a Sell and believe this share price will drop from its current level to $83.11.
-
What Is Colgate-Palmolive's Price Target?
The price target for Colgate-Palmolive over the next 1-year time period is forecast to be $104.73 according to 16 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is CL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Colgate-Palmolive is a Hold. 8 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CL?
You can purchase shares of Colgate-Palmolive via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Colgate-Palmolive shares.
-
What Is The Colgate-Palmolive Share Price Today?
Colgate-Palmolive was last trading at $87.38 per share. This represents the most recent stock quote for Colgate-Palmolive. Yesterday, Colgate-Palmolive closed at $87.54 per share.
-
How To Buy Colgate-Palmolive Stock Online?
In order to purchase Colgate-Palmolive stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
